Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0M | $82.6M | $72.2M | $64.7M | $53.3M | $55.3M | $58.0M | $91.3M | $117M | $134M |
| Revenue growth | — | -8.2% | -12.6% | -10.4% | -17.5% | 3.6% | 4.9% | 57.5% | 28.4% | 14.2% |
| Gross profit | $62.3M | $50.1M | $43.5M | $42.5M | $34.4M | $32.5M | $32.1M | $55.5M | $68.2M | $84.3M |
| Gross margin | 69.2% | 60.6% | 60.2% | 65.7% | 64.5% | 58.8% | 55.4% | 60.8% | 58.2% | 62.9% |
| Operating income | -$7.55M | -$37.8M | -$60.1M | -$2.25M | -$751K | -$3.85M | -$6.75M | -$10.2M | -$12.1M | $7.28M |
| Operating margin | -8.4% | -45.8% | -83.2% | -3.5% | -1.4% | -7.0% | -11.7% | -11.1% | -10.3% | 5.4% |
| Net income | -$19.5M | -$52.4M | -$70.1M | -$8.22M | -$7.02M | -$4.85M | -$8.48M | $660K | -$16.4M | $4.97M |
| Net margin | -21.7% | -63.4% | -97.1% | -12.7% | -13.2% | -8.8% | -14.6% | 0.7% | -14.0% | 3.7% |
| EPS (diluted) | -$18.46 | -$34.76 | -$5.97 | -$0.63 | -$0.25 | -$0.06 | -$0.09 | $0.01 | -$0.12 | $0.03 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.4M | -$543K | $1.21M | -$413K | -$731K | $439K | -$5.34M | -$9.52M | -$11.9M | $12.5M |
| Capital expenditures | $5.83M | $1.64M | $624K | $879K | $1.54M | $2.12M | $1.76M | $1.46M | $4.11M | $2.38M |
| Free cash flow | -$20.2M | -$2.18M | $588K | -$1.29M | -$2.28M | -$1.68M | -$7.11M | -$11.0M | -$16.0M | $10.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.58M | $2.86M | $6.80M | $5.24M | $2.34M | $18.2M | $20.3M | $5.71M | $6.20M | $17.1M |
| Total assets | $144M | $106M | $46.4M | $43.2M | $41.5M | $54.7M | $60.2M | $92.6M | $93.8M | $94.1M |
| Total liabilities | $151M | $164M | $90.2M | $87.4M | $27.0M | $23.8M | $26.1M | $41.3M | $50.9M | $43.2M |
| Long-term debt | $119M | $67.1M | $77.9M | $76.2M | — | $11.8M | $9.69M | $17.2M | $22.0M | $11.0M |
| Shareholders' equity | -$7.07M | -$58.7M | -$43.8M | -$44.2M | $14.5M | $30.9M | $34.2M | $51.3M | $43.0M | $51.0M |
| Retained earnings | -$92.5M | -$145M | -$215M | -$223M | -$230M | -$235M | -$244M | -$243M | -$259M | -$254M |
| Shares (wtd avg diluted) | 1.06M | 1.51M | 11.7M | 13.2M | 28.5M | 85.5M | 94.1M | 127M | 134M | 150M |
Every figure is extracted from Xtant Medical Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.